Key Metrics of Citius Pharmaceuticals Inc.
Revenue—FY 2023
Operating income−$36.7M▼ 10.3% YoY
Net profit−$32.5M▲ 3.3% YoY
Shareholders' equity$84.7M
Market cap$15.5MCTXR · $0.56
Competitors10identified
About Citius Pharmaceuticals Inc.
Sectors
Company details
- Listed
- Nasdaq: CTXR
Operational Areas of Citius Pharmaceuticals Inc.
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameCitius Pharmaceuticals Inc.
TickerCTXR
ExchangeNasdaq
CountryUnited States
SEC CIK0001506251
Listed since—
IndustryBiotechnology: Pharmaceutical Preparations
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
CTXR · Nasdaq · SEC CIK 0001506251
Last price · 31 Oct 2026
$0.56
+4.07%
Market cap$15.5M
P/E—On FY 2023 diluted EPS
Volume403,040
SectorHealth CareBiotechnology: Pharmaceutical Preparations
Country · IPOUnited States
CTXR share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Citius Pharmaceuticals Inc.
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
 Becton Dickinson |
Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | twistbioscience.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.